Japanese researchers replicating the research of Denise Faustman,MD, have noted that islets increased in size in“reversed” non-obese diabetic mice after a pancreaticbeta cell transplant.
“In this study, we aimed to “reverse”hyperglycemic state to normoglycemic state in autoimmune diabeticmice,” write the researchers. “Since beta cells aredestructed by effector cells, at least . . . two factors arenecessary when “reversing” hyperglycemia in autoimmunediabetes: depletion of effector cells and enhancement of beta-cellregeneration.”
The researchers attempted to send the type 1 mice into remission bycombining CFA (complete Freund’s adjuvant) administration andtransplanted beta cells.
Type 1 mice between the ages of 18 to 40 weeks of age with recentonset of type 1 were injected with the adjuvant and beta cellcombination.
“Five out of seven mice [71 percent] receiving [beta cells andCFA] achieved normoglycemia by 120 days post-treatment,” writethe researchers.
Histological examination of pancreases from “reversed”mice showed a decrease in the number of islets, but each of theislets was markedly bigger.
“The size of the islets in ‘reversed’ mice wasfive to 10 times larger than that in control mice,” write theresearchers. “The mechanism of inducing remission is unclearat this moment, but this methodology will give us a clue of a noveltherapy for type 1 diabetes.”